The Role of the Pharmacist and Pharmacogenomics in the Care of Seriously Ill Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- Mayo Clinic
- Enrollment
- 2
- Locations
- 1
- Primary Endpoint
- Change in symptom control
Study Overview
Brief Summary
Researchers are trying to learn more about how pharmacists and pharmacogenomic testing can help care providers improve control of symptoms and quality of life in seriously ill patients.
Detailed Description
Participants in the study will be randomized to A) standard of care, B) standard of care with medication therapy management provided by a pharmacist, or C) standard of care with medication therapy management by a pharmacist who has access to the patient's pharmacogenomics profile accessible to guide them. We will be measuring level of symptom control in each group over the subsequent 6 months.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •English speaking
- •Age 18 years and older
- •Palliative Medicine is consulted for the first time in either the outpatient setting for symptom management and plan to continue to follow up with the Palliative Medicine team in the outpatient setting for the foreseeable future.
- •Insurance accepted at Mayo Clinic Arizona.
- •Live within metro Phoenix area.
Exclusion Criteria
- •Vulnerable adults
- •Under 18 years of age
- •Pregnant Patients
- •Subjects whose medical insurance requires use of specific pharmacies
- •Non English Speaking Patients
- •Patients that lack capacity for medical decision making
- •Patients who live outside the metro Phoenix area
- •Patients who are lost to follow up secondary to enrolling in hospice, die or failure to show or answer surveys within 2 months of enrollment.
- •Patient with uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
- •Patient's previously established within the Palliative Medicine Clinic who receive ongoing Palliative Medicine services.
Arms & Interventions
Control Group
Standard care by Palliative Medicine physician
Intervention Group A
Standard care by Palliative medicine physician plus pharmacist review of medications
Intervention: Pharmacist review (Other)
Intervention Group B
Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review
Intervention: Pharmacogenomics testing (Diagnostic Test)
Intervention Group B
Standard care by Palliative medicine plus pharmacogenomics testing and pharmacist review
Intervention: Pharmacist review (Other)
Outcomes
Primary Outcomes
Change in symptom control
Time Frame: Baseline,1, 2, 4, and 6 months
Measure using the self-reported Edmonton Symptom Assessment scale where a lower score indicates good symptom control and higher score indicates poor symptom control
Secondary Outcomes
No secondary outcomes reported
Investigators
Mark K. Edwin
Principal Investigator
Mayo Clinic